Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
Plain-language summary
Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.
Who can participate
Age range12 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Must have ≥ 50% hair loss on scalp due to Alopecia Areata (AA) and be intolerant or have inadequate response to all commonly used AA therapies accessible in the country. Additional eligibility criteria may be required.